Optimi Health is a Canadian pharmaceutical manufacturer that produces GMP-grade psilocybin and MDMA capsules for regulated psychedelic-assisted therapies. The company is vertically integrated, growing psilocybin mushrooms, extracting active pharmaceutical ingredients, and formulating finished drug products at its facilities in British Columbia. Optimi Health offers MDMA capsules for PTSD treatment and botanical psilocybin capsules for treatment-resistant depression. The company sells these controlled substances through distribution partners to authorized prescribers, clinical trial sponsors, and research institutions. Optimi Health recognizes revenue upon the export and delivery of drug products to markets where these therapies are legally permitted. Australia serves as the primary commercial market, where psychiatrists prescribe products under the Authorised Prescribers Scheme. The company also supplies clinical trials in Canada, Israel, and the UK. Optimi Health leverages its Health Canada Drug Establishment Licence to facilitate international exports and validate its production capabilities. The growth strategy focuses on increasing shipment volumes to Australia, securing global clinical supply agreements, and preparing for entry into the U.S. market following potential DEA rescheduling. Optimi Health aims to reduce unit costs by automating its manufacturing processes to increase throughput.